The effect of the highly specific targeting of the T315I mutation observed with olverembatinib seems to be more pronounced than with ponatinib, which was reported to exert antileukemic activity regardless of baseline BCR-ABL1 mutation status in the phase 2 ponatinib Ph-positive acute lymphoblastic leukemia (ALL) and CML evaluation (PACE) and Optimizing Ponatinib Treatment in CML (OPTIC) studies [7, 8]; and asciminib, which targets the T315I mutation but requires higher doses in both in vitro and in vivo studies [26, 27]. Here, ABL1 is linked to acute lymphoblastic leukemia.